Sodium channel blockers for type 2 Brugada patterns

A spontaneous type 2 Brugada ECG pattern is a finding to investigate, not a diagnosis to announce. The saddleback ST-segment elevation in the right precordial leads can overlap with normal variation, lead placement, pectus excavatum, right-ventricular outflow tract abnormalities, fever, electrolyte disturbance and exposure to sodium channel blockers. Repeating the ECG, obtaining higher right-sided leads and comparing older tracings often clarify whether the pattern is reproducible.

Sodium channel blocker challenge is used to unmask a diagnostic type 1 pattern in people whose resting ECG is suspicious but not definitive. Evidence on sodium channel blockers in type 2 Brugada pattern supports a useful role for ajmaline, with flecainide and pilsicainide as alternatives when appropriate. The test must be interpreted alongside symptoms, family history and structural-heart assessment: a positive ECG response and a negative challenge carry different meanings, and neither removes the need for specialist judgement.

Why a type 2 pattern needs context

Under current criteria, a convincing drug-induced type 1 pattern can establish Brugada syndrome in the hands-on setting. A spontaneous type 2 pattern is less specific, and its significance rises when there is unexplained ventricular fibrillation, syncope, nocturnal breathing arrest or a relevant family history. An isolated pattern in an asymptomatic person does not automatically justify an intravenous drug challenge.

Before challenge, reviewers should inspect medication lists, including flecainide, procainamide, certain antidepressants and antipsychotics, and ask about fever and recent ischaemic symptoms. Repeat 12-lead and high V1–V2 ECGs, check electrolytes and consider ambulatory recording to identify intermittent type 1 features. Echocardiography or other imaging may be needed if structural disease is suspected; coronary assessment follows the clinical presentation.

In Australian consultations, patients may say “blackout” or “near-faint” for events that range from brief loss of consciousness to presyncope. That everyday language is useful, but the distinction between a witnessed collapse, injury, seizure-like activity and palpitations must be resolved. A carefully taken history can do more for diagnostic specificity than repeating a borderline ECG at an arbitrary interval.

Choosing the challenge drug

Ajmaline is generally the preferred intravenous challenge because it is short acting and has the strongest diagnostic yield in many published series. Units use standardised protocols with staged dosing, continuous ECG and blood-pressure monitoring, and ready access to defibrillation. The objective is diagnostic ECG conversion, not deliberate induction of ventricular fibrillation, although VF is a rare and serious risk.

Flecainide can be given intravenously in specialist centres or orally when an outpatient protocol is selected; pilsicainide is another option where available. An oral challenge is convenient but slower, less predictable and often less sensitive, and its longer effects complicate recovery. Procainamide has been used, yet availability, QT effects and tolerability now restrict its role in many Australian centres.

Drug selection depends on baseline rhythm, QT interval, ventricular function, conduction disease, renal and hepatic function, and whether the person already takes a sodium channel blocker for another arrhythmia. Flecainide exposure can itself exaggerate the Brugada-like ECG, so stopping it solely to obtain a cleaner test is unsafe without an electrophysiology plan. Known structural heart disease or unexplained syncope requires particular caution and may shift the discussion toward direct clinical evaluation.

What diagnostic yield actually means

Diagnostic yield is not identical to sensitivity. Yield asks how often a test produces a positive result in the selected group; sensitivity asks how often it detects disease among truly affected people. The many published Brugada studies use different baseline ECGs, dosing ceilings, endpoints and reference standards. Their percentages therefore need comparison cautiously, especially when a cohort contains only strongly suspicious type 2 patterns.

For convincing type 2 patterns, ajmaline generally produces the highest estimates, often in the high 80% to 90% range, with some pooled analyses reporting higher. Intravenous flecainide often yields less, while oral protocols and pilsicainide vary with dose, timing and local experience. Selection bias can inflate performance because patients who later show an unmistakable type 1 ECG are more likely to be tested. A negative challenge after an incomplete protocol is consequently weaker evidence than a negative result after a properly completed assessment.

Percentages also conceal denominators and false positives. A non-clinical RTP comparison methodology illustrates how a percentage can look persuasive while describing a different underlying population; it is not evidence about Brugada. Clinical interpretation should instead ask how many participants truly had Brugada syndrome, whether an independent electrophysiology endpoint was used, and what arrhythmia or follow-up outcome followed. The absolute number of positive and negative results is often more informative than the headline proportion.

Making the test safe in Australia

A challenge belongs in a tertiary centre with an electrophysiology team, continuous rhythm and haemodynamic monitoring, intravenous access, resuscitation equipment and an agreed emergency protocol. Written consent should cover the risk of arrhythmia, possible resuscitation and alternatives to drug provocation. Medicare-subsidised GP and specialist consultations can support access, but they do not determine suitability. Complex or equivocal cases are usually discussed at a public hospital electrophysiology service, while private cardiology may provide initial assessment.

Distance materially affects planning. For someone living in regional New South Wales, northern Queensland, central Australia, far western Tasmania or a remote South Australian community, travel may leave little margin if VF occurs. Telehealth can review records and arrange transfer, but it cannot substitute for onsite monitoring. Ambulance and emergency-department response times should be considered in the referral letter, and the testing hospital needs a clear route back to local follow-up.

Access must include culturally safe care for Aboriginal and Torres Strait Islander patients, with an accredited interpreter when preferred and time for kinship-supported decision-making where appropriate. Remote travel, fasting and an unfamiliar hospital can make consent and recovery harder; bringing a support person and combining the visit with other cardiology needs may reduce disruption. Private testing can be faster in some cities, but cost and location should not override clinical necessity.

Medicine supply is another Australian-specific issue. Ajmaline and pilsicainide may be held in a tertiary hospital pharmacy or obtained through a Therapeutic Goods Administration special-access pathway rather than a routine community PBS prescription. Flecainide is more familiar and may already be PBS-listed for another indication, yet using it as a challenge still requires stock and monitoring arrangements. The referring clinician should confirm availability, renal dosing where applicable, transport, observation time and responsibility for reviewing an abnormal ECG.

Turning the result into care

A positive challenge should prompt review by a cardiologist with Brugada expertise, not an immediate search for inherited causes. Management begins with a written fever plan, emergency instructions and avoidance of agents that can worsen the phenotype, followed by genetic counselling and targeted family evaluation. An implantable cardioverter-defibrillator is considered mainly for survivors of ventricular fibrillation or selected high-risk presentations; the ECG result alone does not justify implantation and does not accurately quantify future arrhythmia risk.

An equivocal study needs a documented plan: repeat high-quality tracings, ambulatory monitoring, review of previous records and assessment for an alternate diagnosis. Until clarified, clinicians should consider whether syncope, exercise-related events or nocturnal symptoms warrant urgent review. Driving advice must account for the event and state or territory licensing rules, especially for commercial drivers. A negative challenge is not clearance to drive after an unexplained blackout, and patients should never repeat a challenge using borrowed or leftover medication.

If an ICD is already present, elective procedures require coordination among the patient, electrophysiologist, anaesthetist and surgeon. The Journal’s ICD perioperative guidance addresses electrocautery, programming and magnet use in Australian day-surgery and hospital settings. Questions about programming, arrhythmia therapy and postoperative observation should be settled beforehand, while urgent surgery must use an emergency pathway rather than delaying essential care for a routine test.

If you are arranging care for a borderline Brugada ECG, send the referral team the original tracing, previous ECGs, a current medication list, relevant event details and any family history, then request an electrophysiology opinion before provocation testing. Confirm which Australian centre stocks the chosen agent, what monitoring is mandatory, who will manage complications and how follow-up will work after you return home.